• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Denali Therapeutics Inc (NQ: DNLI )

    24.04 -0.05 (-0.21%)
    Streaming Delayed Price Updated: 11:19 AM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Denali Therapeutics Inc

    < Previous 1 2 3 4 Next >
    Denali Therapeutics Stock Gets Technical Rating Upgrade
    Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
    Via Investor's Business Daily
    3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
    Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
    Via InvestorPlace
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    4 Analysts Assess Denali Therapeutics: What You Need To Know
    Via Benzinga
    Denali Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024
    DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    The Latest Analyst Ratings for Denali Therapeutics
    Via Benzinga
    Where Denali Therapeutics Stands With Analysts
    Via Benzinga
    Analyst Expectations for Denali Therapeutics's Future
    Via Benzinga
    Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    To the Moon and Beyond: 7 Stocks With Cosmic Potential
    With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
    Via InvestorPlace
    Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
    Via Benzinga
    Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
    Via Benzinga
    Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces $500 million Private Placement Equity Financing
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
    Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
    Via Benzinga
    3 Biotech Stocks to Buy for the Next Bull Run: February 2024
    These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
    Via InvestorPlace
    Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
    Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today. 
    Via InvestorPlace
    Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
    U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
    B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a  
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
    Via Benzinga
    Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.